Disease duration as an indicator of the efficacy of liraglutide in patients with type 2 diabetes mellitus
SourceJournal of Diabetes Investigation, 9, 4, (2018), pp. 979-980
Article / Letter to editor
Display more detailsDisplay less details
Journal of Diabetes Investigation
SubjectRadboudumc 5: Inflammatory diseases RIHS: Radboud Institute for Health Sciences
Comment on the article of Usui et al. Retrospective cohort study of obese patients with type 2 diabetes mellitus (n = 69) demonstrates that the glucose-lowering effect of liraglutide as add on therapy to insulin relies on the remaining beta-cell function in type 2 diabetes. Shorter disease duration implies a more favourable prognosis for response on instantaneous substitution of insulin with liraglutide (HR 2.39 (95% CI: 1.20-4.76).
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.